Merck, Seattle Genetics form partnerships worth $4.5B focused on two cancer drugs

Pharmaceutical company Merck and Bothell, Washington-based Seattle Genetics have formed a partnership to advance two key cancer therapies. The first involves expanding Tukysa, the drug approved for certain metastatic HER2-positive breast cancers, beyond the North American and European markets. They also plan to collaborate on the development of ladiratuzumab vedotin, which aims to treat certain types of breast cancer and other solid tumors.   

READ THE STORY at MedCity News »